Study of a new drug for recurrent small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of small cell lung cancer.
- Your cancer must have come back after at least 4 cycles of first-line chemotherapy with etoposide and platinum, with the relapse happening between 30 days and 6 months after your last treatment.
- You need to have at least one tumor that can be measured on scans (like a CT or MRI).
- You must be in generally good health, with an ECOG performance status of 0 or 1, and expected to live at least 3 more months.
- Your liver and kidney function, blood counts, and other organ systems must be within certain limits as determined by blood tests.
- You cannot have had prior treatment with irinotecan, topotecan, or similar drugs, and you must not have active infections, severe heart or lung disease, or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This study tests whether adding a new investigational drug (IBB0979) to the standard chemotherapy topotecan helps people with small cell lung cancer whose cancer has come back after earlier treatment. The goal is to see if the combination is more effective than topotecan alone.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Hear when a new Relapsed Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.